Fennec Pharmaceuticals Inc. (FENC) - 2024 Annual Report Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2024, for Fennec Pharmaceuticals Inc., a commercial-stage biopharmaceutical company. The Company's sole product is PEDMARK® (sodium thiosulfate injection), the first and only FDA-approved therapy to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharma UK Limited to commercialize PEDMARQSI® (the European brand name) in Europe, Australia, and New Zealand.
Key Financial Metrics
| Metric (in thousands USD) | 2024 | 2023 |
|---|---|---|
| Total Revenue | $47,538 | $21,252 |
| Product Sales, Net | $29,580 | $21,252 |
| Licensing Revenue | $17,958 | $0 |
| Net Loss | $(436) | $(16,045) |
| Operating Income | $2,568 | $(12,771) |
| Cash and Equivalents (Year End) | $26,634 | $13,269 |
| Working Capital | $37,205 | $19,305 |
| Long-Term Debt (Principal) | $18,206 | $30,000 |
Note: The Company recorded $9.3 million in discounts and allowances against gross product sales of $38.9 million in 2024. Gross margin on product sales was approximately 89% ($26.4M gross profit / $29.6M net sales).
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased by 124% to $47.5 million, driven by a $18.0 million licensing revenue recognition from the Norgine upfront payment and a 39% increase in net product sales ($29.6M vs $21.3M) due to expanded market penetration and focus on the Adolescent and Young Adult (AYA) population.
- Profitability Improvement: The Company narrowed its net loss significantly from $16.0 million in 2023 to $0.4 million in 2024. This was the first year of positive operating income ($2.6 million).
- Debt Reduction: In December 2024, the Company repaid $13.0 million of its Petrichor convertible notes, reducing total long-term debt principal from $30.0 million to $18.2 million.
- Expense Growth: Selling and marketing expenses rose 52% to $18.4 million, and General and Administrative (G&A) expenses increased 12% to $23.1 million, reflecting commercialization efforts and legal costs related to patent litigation.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes current cash resources of $26.6 million, bolstered by the Norgine upfront payment, are sufficient to fund operations for at least the next 12 months. The Company anticipates continued losses as it scales commercialization in the U.S. and prepares for international launches.
Key Developments:
- Norgine Launch: Norgine launched PEDMARQSI in Germany in early 2025 and received positive final draft guidance from NICE (UK) in December 2024.
- Patent Litigation: Ongoing litigation against CIPLA regarding generic ANDA filings. The Company has narrowed its claims to specific patents (US '018 and '793) and maintains Orphan Drug Exclusivity until September 2029, which blocks FDA approval of a generic version regardless of patent litigation outcomes.
Risks and Contingencies:
- Single Product Dependence: The Company's entire financial future relies on the commercial success of PEDMARK/PEDMARQSI.
- Reimbursement: Sales depend heavily on third-party payer coverage and reimbursement rates, which are subject to cost-containment pressures.
- Manufacturing: The Company relies entirely on third-party contract manufacturers; any disruption could halt supply.
- Intellectual Property: While Orphan Drug Exclusivity provides a 7-year barrier, the Company faces ongoing patent challenges and the risk of patent invalidation.
Investor Verification Checklist
- Norgine Revenue Recognition: Verify the accounting treatment of the $43.2 million upfront payment, specifically the allocation between immediate license revenue ($18.0M) and deferred contract liabilities ($24.8M) based on standalone selling prices.
- Reimbursement Rates: Monitor the actual reimbursement rates achieved by payers versus the list price, given the $9.3 million in discounts and allowances recorded in 2024.
- Credit Risk: Review the $3.8 million allowance for expected credit losses, particularly regarding international distributors, as noted in the auditor's critical audit matters.
- Debt Covenants: Confirm the terms of the remaining $18.2 million Petrichor note, including interest rates (Prime + 4.5%) and conversion features.
- Patent Litigation Status: Track the progress of the CIPLA ANDA litigation and any potential settlements that could impact market exclusivity beyond the Orphan Drug period.